JAK2 and acquired polycythemia vera: However, the more tolerable HDAC inhibitor, givinostat, is expected to be assessed in a phase 3 clinical trial for the treatment of PV, suggesting that givinostat may be a potential therapeutic approach for the treatment of JAK2-altered ALL when in combination with chemotherapy or type-I JAK2 inhibition (Chifotides et al., 2020).